Items where Author is "Roos, I."

Article

(2026) Causal effects of multiple sclerosis therapies in left-truncated registry data. Multiple sclerosis (Houndmills, Basingstoke, England). pp. 1052-1068. ISSN 1477-0970 (Electronic) 1352-4585 (Print) 1352-4585 (Linking)

(2026) Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry. Therapeutic Advances in Neurological Disorders. p. 17562864261430084. ISSN 1756-2856 (Print) 1756-2864 (Electronic) 1756-2856 (Linking)

(2026) Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study. Journal of Neurology Neurosurgery and Psychiatry. pp. 763-773. ISSN 0022-3050

(2026) Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry. Journal of Neurology. p. 15. ISSN 0340-5354

(2026) Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder. Neurology. p. 12. ISSN 0028-3878

(2026) Predicting disease progression in multiple sclerosis with clinically accessible information and technology. Journal of Neurology. p. 18. ISSN 0340-5354

(2026) Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study. Cns Drugs. pp. 1011-1025. ISSN 1172-7047

(2025) Disease course after pregnancy in women with progressive multiple sclerosis symptoms. Multiple Sclerosis Journal. pp. 1439-1451. ISSN 1352-4585

(2025) Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024). Multiple Sclerosis Journal. pp. 1088-1101. ISSN 1352-4585

(2025) Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry. pp. 50-58. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2025) Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study. Journal of Neurology. p. 339. ISSN 1432-1459 (Electronic) 0340-5354 (Print) 0340-5354 (Linking)

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) How patients with neuromyelitis optica spectrum disorder accumulate disability. Multiple Sclerosis Journal. pp. 1158-1160. ISSN 1352-4585

(2024) Preserving neurological function in patients at high risk and low risk of aggressive MS. Multiple Sclerosis Journal. pp. 631-634. ISSN 1352-4585

(2024) Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD. Neurology. e209940. ISSN 1526-632X (Electronic) 0028-3878 (Linking)

(2024) A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Journal of Neurology. p. 12. ISSN 0340-5354

(2024) A standardised definition of progression independent of relapse activity in multiple sclerosis. Multiple Sclerosis Journal. pp. 442-445. ISSN 1352-4585

(2023) Comparative effectiveness in multiple sclerosis: A methodological comparison. Multiple Sclerosis Journal. pp. 326-332. ISSN 1352-4585

(2023) Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 707-717. ISSN 0022-3050

(2023) Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 875-883. ISSN 1352-4585

(2023) Effect of high-efficacy therapy on the course of disability in paediatric-onset multiple sclerosis. Multiple Sclerosis Journal. pp. 103-105. ISSN 1352-4585

(2023) Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. Journal of Neurology Neurosurgery and Psychiatry. pp. 1004-1011. ISSN 0022-3050

(2023) Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. pp. 1014-1024. ISSN 1351-5101

(2022) Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. NEUROLOGY. ISSN 0028-3878

(2022) The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Journal. pp. 967-970. ISSN 1352-4585